ViiV Healthcare Company drugs
8 results
Apretude (cabotegravir)
(Cabotegravir)ViiV Healthcare Company
Usage: APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to decrease the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk. A negative HIV-1 test is required before starting APRETUDE.
Cabenuva (cabotegravir and rilpivirine)
(cabotegravir and rilpivirine)ViiV Healthcare Company
Usage: CABENUVA is indicated for the treatment of HIV-1 infection in adults and adolescents (ages 12 and older, weighing at least 35 kg) as a complete regimen to replace existing antiretroviral therapy in those who are virologically suppressed and have no history of treatment failure or resistance.
Dovato (dolutegravir sodium and lamivudine)
(dolutegravir sodium and lamivudine)ViiV Healthcare Company
Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (ages 12 and older, weighing at least 25 kg) with no prior antiretroviral therapy or to replace the current regimen in those who are virologically suppressed without resistance concerns.
Juluca (dolutegravir sodium and rilpivirine hydrochloride)
(dolutegravir sodium and rilpivirine hydrochloride)ViiV Healthcare Company
Usage: JULUCA is indicated for the treatment of HIV-1 infection in adults as a complete regimen. It is intended for patients who are virologically suppressed on a stable antiretroviral regimen for at least 6 months, with no treatment failures or resistance substitutions to JULUCA's components.
Rukobia (fostemsavir tromethamine)
(fostemsavir tromethamine)ViiV Healthcare Company
Usage: RUKOBIA is indicated for treating HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1, specifically for those failing their current antiretroviral regimen due to resistance, intolerance, or safety issues, in combination with other antiretrovirals.
Tivicay pd (dolutegravir sodium)
(dolutegravir sodium)ViiV Healthcare Company
Usage: TIVICAY and TIVICAY PD are indicated for the treatment of HIV-1 in adults and pediatric patients (aged ≥4 weeks, weighing ≥3 kg) in combination with other antiretrovirals, including as a regimen replacement for virologically suppressed adults with no treatment failure history.
Triumeq (abacavir sulfate, dolutegravir sodium, lamivudine)
(abacavir sulfate, dolutegravir sodium, lamivudine)ViiV Healthcare Company
Usage: TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance due to insufficient dolutegravir dosage.
Trizivir (abacavir sulfate, lamivudine, and zidovudine)
(abacavir sulfate, lamivudine, and zidovudine)ViiV Healthcare Company
Usage: TRIZIVIR is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, either alone or in combination with other antiretrovirals. However, data are limited for its use alone in patients with baseline viral loads exceeding 100,000 copies per mL.